Merck, Lilly Vow To Press On With CETP, Despite Dalcetrapib Disaster
This article was originally published in The Pink Sheet Daily
Executive Summary
Early termination of a large outcomes study of Roche’s CETP inhibitor dalcetrapib raises doubts about others in the class. Some analysts speculate that Eli Lilly may opt not to continue with its evacetrapib, but the company says it remains committed.
You may also be interested in...
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: